Table II.
Characteristics | TB alone | SB alone | TB + SB | P-value |
---|---|---|---|---|
No. of patients | 41 (23.7) | 28 (16.2) | 104 (60.1) | |
Age (years) | 68 (61–73) | 69 (66–73) | 72 (66–79) | 0.66a |
PSA (ng/ml) | 7.55 (5.12–10.36) | 9.38 (6.21–14.16) | 13.78 (3.65–18.17) | 0.008a |
Prostate volume (ml) | 47.65 (30.65–62.35) | 35.15 (25.06–46.38) | 37.57 (24.46–53.93) | 0.020a |
PSAD (ng/ml2) | 0.13 (0.10–0.17) | 0.19 (0.12–0.34) | 0.26 (0.15–0.40) | 0.028a |
DRE (No. of patients) | 0.028 | |||
Normal | 37 (90.2) | 18 (64.3) | 84 (80.8) | |
Abnormal | 4 (9.8) | 10 (35.7) | 20 (19.2) | |
TRUS (No. of patients) | 0.002 | |||
Normal | 33 (80.5) | 12 (42.9) | 55 (52.9) | |
Abnormal | 8 (19.5) | 16 (57.1) | 49 (47.1) | |
Biopsy Gleason score (no. of patients) | 0.261 | |||
<7 | 23 (56.1) | 15 (53.6) | 61 (58.7) | |
≥7 | 18 (43.9) | 13 (46.4) | 43 (41.3) |
Data presented are median (interquartile range) or number (%). TB, targeted biopsy; SB, systematic biopsy; PSA, prostate-specific antigen; PSA density; DRE, digital rectal examination; TRUS, transrectal ultrasound.
These values were calculated by t-test, and the remaining P values were calculated by chi-square test.
TB, targeted biopsy; SB, systematic biopsy.